Skip to main content
Nuclear Medicine and Molecular Imaging logoLink to Nuclear Medicine and Molecular Imaging
. 2015 Dec 1;51(2):190–192. doi: 10.1007/s13139-015-0384-7

F-18 FDG PET Findings for Vogt-Koyanagi-Harada Disease

Hye Lim Park 1, Ie Ryung Yoo 1,, Sonya Youngju Park 1
PMCID: PMC5429289  PMID: 28559946

Abstract

Vogt-Koyanagi-Harada disease is a rare multisystemic granulomatous autoimmune disorder affecting pigmented tissues such as the choroid, meninges, inner ear, and the skin. Neurologic symptoms are usually mild. Clinical manifestations include generalized muscle weakness, headache, meningismus, vertigo, decreased visual acuity, hearing loss and mental changes ranging from mild confusion to psychosis, hemiparesis, dysarthria, and aphasia. Seizures are very rare. We describe a case of 18F-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET) and software-fused PET-magnetic resonance imaging (MRI) in Vogt-Koyanagi-Harada disease with seizure.

Keywords: Vogt-Koyanagi-Harada disease, FDG, Positron-emission tomography, Magnetic resonance imaging, Seizure


Fig. 1.

Fig. 1

A 47-year-old man visited the neurology clinic, presenting with three episodes of generalized tonic-clonic seizures. Cerebrospinal fluid study for evaluation of meningitis was normal. On brain diffusion magnetic resonance imaging (MRI) for excluding central nervous system infection and metabolic encephalitis, there were multifocal sulcal high signal intensity (SI) suggestive of meningitis or leptomeningeal metastasis (a, b). To exclude primary malignancy, 18F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) was performed from the vertex to thigh. There were multifocal FDG uptake areas along the cerebral sulci. Software-fused PET-MRI images (c, d) and PET images (e, f) show focal FDG uptake in corresponding sulcal high SI areas on MRI. The patient also complained of redness of bilateral eyes (anterior uveitis and optic disc swelling), hearing loss and alopecia from 6 months ago. The abovementioned symptoms fulfilled the diagnostic criteria for Vogt-Koyanagi-Harada (VKH) disease. The patient underwent steroid pulse therapy and his symptoms improved gradually. One month follow-up MRI images showed regressed sulcal high SI. VKH disease can be categorized into three levels, on the basis of clinical examination. The complete disease is bilateral ocular involvement with neurologic/auditory findings and integumentary finding. Incomplete disease is bilateral ocular involvement with either neurologic/auditory findings or integumentary finding. Probable disease is isolated ocular disease [1]. The pathophysiology of VKH disease has not yet been elucidated, although T cell-mediated autoimmune disorder against self-antigens in melanocytes is strongly suggested [2]. Neurologic symptoms in VKH disease are variable, but usually mild. Headache, muscle weakness, meningismus, vertigo, hearing loss, and mental changes can be noted, while seizures are very rare [3]. The focal FDG uptake in leptomeninges may be related to granulomatous change against leptomeningeal melanin-containing cells. MRI findings of VKH disease with neurologic symptoms were reported. Most cases showed pachymeningeal or leptomeningeal enhancement and thickening [46]. Some showed parenchymal involvement and hyperintense lesions in periventricular white matter [7]. To the best of our knowledge, this is the first case in the literature of brain involvement from VKH disease demonstrated on F-18 FDG PET and software-fused PET-MRI

Compliance with Ethical Standards

Conflicts of Interest

The authors Hye Lim Park, Ie Ryung Yoo, and Sonya Youngju Park declare that they have no conflict of interest.

Ethical Statement

This study was performed in accordance with the regulations of our hospital’s Institutional Review Board, which approved the retrospective design and waived the requirement for informed consent. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.

References

  • 1.Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev. 2014;13:550–5. doi: 10.1016/j.autrev.2014.01.023. [DOI] [PubMed] [Google Scholar]
  • 2.Damico FM, Bezerra FT, Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009;72:413–20. doi: 10.1590/S0004-27492009000300028. [DOI] [PubMed] [Google Scholar]
  • 3.Iwata NK, Hayashi T, Numaga J, Yamamichi N, Sakurai M, Kanazawa I. Fits and deafness. Lancet Neurol. 2002;1:387–8. doi: 10.1016/S1474-4422(02)00165-5. [DOI] [PubMed] [Google Scholar]
  • 4.Lohman BD, Gustafson CA, McKinney AM, Sarikaya B, Silbert SC. MR imaging of Vogt-Koyanagi-Harada syndrome with leptomeningeal enhancement. AJR Am J Neuroradiol. 2011;32:E169–71. doi: 10.3174/ajnr.A2279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sheriff F, Narayanan NS, Huttner AJ, Baehring JM. Vogt-Koyanagi-Harada syndrome: a novel case and brief review of focal neurologic presentations. Neurol Neuroimmunol Neuroinflamm. 2014;1 doi: 10.1212/NXI.0000000000000049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Han HJ, Kim HY, Park JH, Lee EJ, do Kim G, Shin DI. Magnetic resonance imaging of pachymeningeal enhancement in Vogt-Koyanagi-Harada disease. Neurol Sci. 2010;31:785–8. doi: 10.1007/s10072-010-0236-2. [DOI] [PubMed] [Google Scholar]
  • 7.Keles S, Ogul H, Pinar LC, Kantarci M. Teaching neuroimages: cerebral white matter involvement in a patient with Vogt-Koyanagi-Harada syndrome. Neurology. 2013;81:e85–6. doi: 10.1212/WNL.0b013e3182a43b01. [DOI] [PubMed] [Google Scholar]

Articles from Nuclear Medicine and Molecular Imaging are provided here courtesy of Springer

RESOURCES